Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its drug Leqembi (lecanemab), an amyloid-beta (Aβ)-targeting therapy indicated for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). This marks a significant milestone in the treatment of Alzheimer’s disease, as Leqembi is positioned as the first disease-modifying treatment for AD.
Leqembi is designed to target both soluble and insoluble Aβ aggregates, including protofibrils and fibrils, thereby reducing the formation of Aβ plaques in the brain. The drug has garnered full approval in the US since July 2023 and received a similar nod in Japan in September of the same year.
Eisai is at the forefront of the global development and regulatory filing for Leqembi. The commercialization and promotion efforts will be a joint responsibility of Eisai and Biogen, with Eisai holding the final decision-making power and taking the lead in marketing the drug in China.- Flcube.com
